4D Molecular Therapeutics, Inc. (FDMT) Stock Price & How to Invest

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, and known as 4DMT) is an Emeryville, California biotech founded in 2013 that engineers adeno-associated virus (AAV) vectors through a directed-evolution platform the company calls Therapeutic Vector Evolution. Its lead candidate, 4D-150, pairs the proprietary R100 vector with a transgene encoding aflibercept plus an RNA interference approach against VEGF-C, delivered by a single in-office intravitreal injection. The goal is to replace repeated monthly or bimonthly anti-VEGF eye injections with one durable treatment. Two Phase 3 wet AMD trials are fully enrolled: 4FRONT-1 randomized 523 patients with topline data guided to Q2 2027, and 4FRONT-2 finished enrollment in June 2026 with more than 500 patients and topline guided to H2 2027. A Phase 3 in diabetic macular edema was slated to start in Q3 2026. Behind the retina franchise sit 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis lung disease, and 4D-725 for alpha-1-antitrypsin deficiency, all of which the company says it is advancing mainly through outside funding rather than its own balance sheet.

The financial picture is the standard clinical-stage arithmetic, with one wrinkle that trips up screeners. 4DMT has never recorded a dollar of product revenue and says so plainly in its filings. Trailing twelve month revenue of roughly $92 million looks substantial, but about $85 million of it was a single upfront payment from Otsuka Pharmaceutical, recognized in Q4 2025 in exchange for Asia-Pacific rights to 4D-150. Ongoing revenue is cost-sharing and reimbursement from that same partner, running around $3.8 million in Q2 2026 against $80.8 million of operating expenses. The company lost roughly $72.9 million in the quarter and about $141.7 million in the first half of 2026, and carries an accumulated deficit near $858 million. Against that burn it held about $431 million in cash and marketable securities at June 30, 2026, plus a Hercules Capital credit facility of up to $200 million with $20 million drawn, and guides that funding into the second half of 2028. That runway reaches past both Phase 3 readouts, which is the whole point of the balance sheet as currently constructed.

Everything concentrates in one molecule and two readouts, so a miss or an ambiguous result in 4FRONT-1 or 4FRONT-2 would remove most of the reason to own the shares. Intravitreal AAV carries a specific safety history around intraocular inflammation and hypotony that has derailed competing programs, and long-term ocular safety in a several-hundred-patient Phase 3 population is a different test than an open-label Phase 2b. Cash burn ran near $70 million a quarter in the first half of 2026, and while the guided runway into the second half of 2028 covers the readouts, it does not cover a commercial launch, so further equity raises or partnerships are likely; a November 2025 offering and an active at-the-market program show how that has been funded before. The competitive bar is also rising, since Roche's Vabysmo and Regeneron's higher-dose Eylea already stretch dosing intervals and aflibercept biosimilars are compressing the price of the incumbent standard. Note the share count trap as well: roughly 55.2 million common shares were outstanding on August 10, 2026, alongside 16.9 million pre-funded warrants exercisable at $0.0001, so per-share and market-cap figures vary by source. On the positive side of the disclosure ledger, the Q2 2026 10-Q stated there were no material legal proceedings outstanding at June 30, 2026, and the company reported no going-concern qualification.

10 analysts publish price targets on FDMT, averaging $29.10 against a $14.54 price as of August 2026, or +100.1%. The published targets run from $18.00 to $37.00, a moderate spread, and the ratings split 10 buy, 2 hold, 0 sell. Over the last six months there has been 1 raise and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full FDMT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on 4D Molecular Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Two fully enrolled Phase 3 wet AMD trials. 4FRONT-1 completed randomization at 523 patients in March 2026 and 4FRONT-2 closed enrollment in June 2026 with more than 500 patients, both ahead of the company's own schedule. The most optimistic published target, $37.00, assumes this works close to its best case.

The case against. Everything concentrates in one molecule and two readouts, so a miss or an ambiguous result in 4FRONT-1 or 4FRONT-2 would remove most of the reason to own the shares. The most pessimistic target, $18.00, is roughly what FDMT is worth if this bites instead.

Read the full bull and bear case on FDMT, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see 4D Molecular Therapeutics, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$92M, of which ~$85M was a one-time Otsuka upfront
• Product revenue: $0, no approved products since inception
• Net loss (Q2 2026): ~$72.9M, ~$141.7M in H1 2026
• R&D expense (Q2 2026): ~$68.3M, versus ~$12.5M G&A
• Cash and marketable securities: ~$431M at June 30, 2026, guided into H2 2028
• Market cap: ~$800M on ~55.2M common shares, ~$1.05B counting pre-funded warrants

Conventional multiples do not apply, because the revenue line is a licensing payment rather than a business. Stripping out roughly $431 million of cash and adding back $20 million of drawn Hercules debt leaves an enterprise value near $390 million on the common-share count, so the market was assigning a few hundred million dollars to a Phase 3 asset in a multi-billion-dollar indication plus four earlier programs. Book value is the only anchor with real content here, at roughly $408 million of stockholders' equity against an accumulated deficit of about $858 million, and the shares traded between roughly $5.97 and $15 over the trailing year.

Other names that sit close to FDMT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get FDMT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so FDMT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where FDMT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

4DMT is a well-funded, one-asset gene therapy story where roughly $431 million of cash buys time to two binary Phase 3 readouts in 2027, and almost nothing else about the stock matters until then.

Whether FDMT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is FDMT a buy or a sell?, and where the stock could go from here in the FDMT stock forecast.

For income investors, whether FDMT pays a dividend and how the payout looks is covered in does FDMT pay a dividend? And to weigh FDMT against a peer, read the full side-by-side comparisons: FDMT vs REGN and FDMT vs HD.